Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

JNJ fell 6% even after Johnson & Johnson beat Q3 estimates and raised its full-year sales and earnings guidance. Disappointing medical device sales overshadowed the beat and drove the selloff.

The split reaction shows where the market's attention sits. Investors punished the MedTech division despite a stronger overall outlook, and the planned DePuy Synthes spinoff adds another layer of near-term uncertainty to that segment.

Oncology offered the counterweight. That business grew 16%+ in Q3, giving the bull case a concrete growth driver outside devices. The Motley Fool piece argues the pullback leaves JNJ attractive at current valuations, pointing to the company's 64-year dividend streak as a reason to hold through the volatility.

Interpretation: a guidance raise paired with a 6% drop suggests the market is pricing device execution risk more heavily than the upgraded forecast. If oncology keeps compounding at that pace, the device weakness may prove a smaller drag on the overall story than the price reaction implies, though that depends on how MedTech trends and how the spinoff unfolds.